

RESEARCH

Open Access

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

Anthony D D'Urzo^{1*†}, Stephen I Rennard^{2†}, Edward M Kerwin^{3†}, Victor Mergel^{4†}, Anne R Leselbaum^{5†}, Cynthia F Caracta^{4†} on behalf of the AUGMENT COPD study investigators

Abstract

Background: Combining two long-acting bronchodilators with complementary mechanisms of action may provide treatment benefits to patients with chronic obstructive pulmonary disease (COPD) that are greater than those derived from either treatment alone. The efficacy and safety of a fixed-dose combination (FDC) of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol fumarate, a long-acting β_2 -agonist, in patients with moderate to severe COPD are presented.

Methods: In this 24-week double-blind study, 1692 patients with stable COPD were equally randomized to twice-daily treatment with FDC aclidinium 400 μ g/formoterol 12 μ g (ACL400/FOR12 FDC), FDC aclidinium 400 μ g/formoterol 6 μ g (ACL400/FOR6 FDC), aclidinium 400 μ g, formoterol 12 μ g, or placebo administered by a multidose dry powder inhaler (Genuair[®]/Pressair[®]). Coprimary endpoints were change from baseline to week 24 in 1-hour morning postdose FEV₁ (FDCs versus aclidinium) and change from baseline to week 24 in morning predose (trough) FEV₁ (FDCs versus formoterol). Secondary endpoints were change from baseline in St. George's Respiratory Questionnaire (SGRQ) total score and improvement in Transition Dyspnea Index (TDI) focal score at week 24. Safety and tolerability were also assessed.

Results: At study end, improvements from baseline in 1-hour postdose FEV₁ were significantly greater in patients treated with ACL400/FOR12 FDC or ACL400/FOR6 FDC compared with aclidinium (108 mL and 87 mL, respectively; $p < 0.0001$). Improvements in trough FEV₁ were significantly greater in patients treated with ACL400/FOR12 FDC versus formoterol (45 mL; $p = 0.0102$), a numerical improvement of 26 mL in trough FEV₁ over formoterol was observed with ACL400/FOR6 FDC. Significant improvements in both SGRQ total and TDI focal scores were observed in the ACL400/FOR12 FDC group at study end ($p < 0.0001$), with differences over placebo exceeding the minimal clinically important difference of ≥ 4 points and ≥ 1 unit, respectively. All treatments were well tolerated, with safety profiles of the FDCs similar to those of the monotherapies.

Conclusions: Treatment with twice-daily aclidinium 400 μ g/formoterol 12 μ g FDC provided rapid and sustained bronchodilation that was greater than either monotherapy; clinically significant improvements in dyspnea and health status were evident compared with placebo. Aclidinium/formoterol FDC may be an effective and well tolerated new treatment option for patients with COPD.

(Continued on next page)

* Correspondence: tonyurzo@sympatico.ca

[†]Equal contributors

¹University of Toronto, Toronto, Canada

Full list of author information is available at the end of the article

(Continued from previous page)

Trial registration: Clinicaltrials.gov NCT01437397.

*Registered trademarks of Almirall S.A., Barcelona, Spain; for use within the US as Pressair[®] and Genuair[®] within all other licensed territories.

Keywords: Acclidinium, Formoterol, COPD, Lung function, Dyspnea, Health status

Background

In patients with chronic obstructive pulmonary disease (COPD), combining bronchodilators with complementary mechanisms of action has the potential to increase lung function and improve symptom management compared to treatment with a single agent [1]. Inhaled long-acting muscarinic antagonists (LAMAs) and long-acting β_2 -agonists (LABAs) are widely used as maintenance treatment in COPD. LAMAs indirectly reduce bronchoconstriction by inhibiting acetylcholine signaling via muscarinic receptors on airway smooth muscle, while LABAs directly stimulate β_2 -adrenoceptors that lead to smooth muscle relaxation. Though the mechanisms of action of these two classes of bronchodilators differ, LAMA/LABA combinations have been a successful treatment option for patients with COPD, improving both spirometric values and health-related quality of life [2-4].

Current treatment guidelines recommend LAMA/LABA combination therapy for COPD patients uncontrolled by bronchodilator monotherapy [1]. Studies investigating the free combination of LAMA and LABA therapies (via two separate inhalers) in patients with COPD have shown improved bronchodilation and reduced rescue medication use compared with monotherapy [2,3,5,6]. Treatment with either acclidinium bromide (a LAMA) 400 μ g twice-daily (BID) or formoterol fumarate (a LABA) 12 μ g twice daily improves lung function and reduces COPD symptoms while being well tolerated [7-12]. As treatment with acclidinium also has been shown to improve health status, exercise endurance, and nighttime symptoms in patients with COPD [11,13], a fixed-dose combination (FDC) comprising acclidinium bromide/formoterol fumarate (Genuair[®]/Pressair[®], approved for delivery of acclidinium monotherapy) may improve lung function, health status, and COPD symptoms while reducing the potential risk for side effects that often occur from increasing doses of monotherapy treatments [1].

The efficacy and safety of twice-daily acclidinium/formoterol FDC in patients with moderate to severe COPD were assessed in a 24-week phase 3, randomized, double-blind study (AUGMENT COPD, Acclidinium/formoterol FUMarate Combination for InvestiGative use in the TreatMENT of Moderate to Severe COPD), the results of which are presented here.


Methods

Study design

This phase 3, randomized, double-blind study in patients with moderate to severe COPD was conducted in 222 centers throughout North America, Australia, and New Zealand (NCT01437397) in accordance with the International Conference on Harmonization/Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol was approved by the Institutional Review Board at each study center, and all patients gave written informed consent before participating in any study procedures. The study comprised a 2- to 3-week run-in period prior to a 24-week double-blind treatment period (Figure 1). Patients were equally randomized to twice-daily acclidinium/formoterol FDC 400/12 μ g, acclidinium/formoterol FDC 400/6 μ g, acclidinium 400 μ g, formoterol 12 μ g, or placebo, administered via a multidose, dry-powder inhaler (Genuair[®]/Pressair[®]). The first patient/first visit was October 4, 2011 and the last patient completed February 6, 2013.

Patients

Patients aged ≥ 40 years were eligible if they were current or former smokers (≥ 10 pack-years) and diagnosed with stable, moderate to severe expiratory airflow obstruction according to GOLD guidelines (postbronchodilator forced expiratory volume in 1 second [FEV₁]/forced vital capacity [FVC] $< 70\%$ and FEV₁ $\geq 30\%$ and $< 80\%$ predicted) [1]. Main exclusion criteria were: COPD exacerbation or respiratory tract infection ≤ 6 weeks (≤ 3 months if hospitalized for exacerbation) before screening; clinically significant respiratory conditions (including asthma); clinically significant cardiovascular (CV) conditions including myocardial infarction (MI) within the previous 6 months; unstable angina; and, unstable arrhythmia that required changes in pharmacological therapy or other intervention within the previous 6 months. Use of long-acting bronchodilators other than investigative treatment was not permitted. Other COPD medications, such as theophylline, inhaled corticosteroids (ICS), oral or parenteral corticosteroids (≤ 10 mg/day or 20 mg every other day of prednisone) were allowed if treatment was stable ≥ 4 weeks prior to screening. Use of albuterol/salbutamol as rescue medication was permitted.



Outcomes and assessments

Coprimary efficacy parameters, assessed by standardized spirometric measurements of lung function [14], were change from baseline to week 24 in 1-hour morning postdose FEV₁ (each FDC versus acclidinium, contribution of formoterol) and change from baseline to week 24 in morning predose (trough) FEV₁ (each FDC versus formoterol, contribution of acclidinium). Secondary efficacy parameters were change from baseline in St. George's Respiratory Questionnaire (SGRQ) total score at week 24 (each FDC versus placebo) and improvement in Transition Dyspnea Index (TDI) focal score at week 24 (each FDC versus placebo).

Additional treatment comparisons for each coprimary parameter included: each acclidinium/formoterol FDC dose versus each monotherapy; each active treatment versus placebo; and acclidinium/formoterol FDC 400/12 µg versus acclidinium/formoterol FDC 400/6 µg. Additional efficacy parameters included: change from baseline in peak FEV₁ at all visits; 12-hour spirometry measurements (in a subset of the intention-to-treat [ITT] population) based on change from baseline in FEV₁ at all study visits; SGRQ and Baseline/Transition Dyspnea Index (BDI/TDI) at all study visits except week 24; rescue medication use; onset of action of bronchodilation; and, daily COPD symptoms assessed by the Exacerbations of Chronic Pulmonary Disease Tool (EXACT)-Respiratory Symptoms (E-RS) questionnaire [15]. A Nighttime Symptoms of COPD Instrument (NISCI) [16,17] and an Early Morning Symptoms of COPD Instrument (EMSCI) [18]—newly developed patient reported outcome measures undergoing empirical testing—were completed twice daily by patients using the electronic diary.

Safety was assessed through reporting of adverse events (AEs), clinical laboratory tests, vital signs,

electrocardiograms (ECGs), and 24-hour 12-lead Holter monitoring. Major adverse cardiovascular events (MACE) were defined as the composite of CV deaths, nonfatal MIs, and nonfatal strokes. MACE were evaluated and classified by an adjudication committee of independent cardiologists who were not participating in the study and were blinded to treatment. To identify all MACE, a list of all AEs that were reported in randomized patients based on standard medical dictionary for regulatory activities (MedDRA) queries of cardiac disorders and cerebrovascular disorders was used.

Assessments for all efficacy and safety outcomes occurred at various timepoints throughout the study (Additional file 1: Table S1).

Statistical analysis

Statistical analyses were performed using SAS[®] version 9.2. All efficacy analyses with the exception of E-RS were based on the ITT population, defined as all randomized patients who took ≥1 dose of study medication and had a baseline and at least one postbaseline FEV₁ assessment. E-RS data were analyzed for the ITT-Exacerbation Population, which included all patients in the randomized population who took at least 1 dose of double-blind investigational product. Change from baseline in bronchodilation outcomes were analyzed by mixed model for repeated measures (MMRM) with treatment group, sex, smoking status, visit, and treatment-group-by-visit interaction as fixed-effect factors and corresponding baseline values and age as covariates, and pre- and postbronchodilator FEV₁ as a covariate for FEV₁ outcomes. A sample size of 1550 (310 per randomized group) was estimated to provide at least 90% power to detect a statistically significant treatment difference of 100 mL (standard deviation of 280 mL) between each FDC dose versus acclidinium

monotherapy in change from baseline at 1-hour morning postdose FEV₁ at week 24, and 65 mL (standard deviation of 240 mL) between each FDC dose versus formoterol monotherapy in the change from baseline in morning pre-dose (trough) FEV₁ at week 24. To control for family-wise type 1 error rate at the 2-sided 5% significance level for the primary and secondary efficacy endpoints, a prespecified multiple comparison strategy was conducted.

The onset of action of bronchodilation in FEV₁ (an additional endpoint defined as a >15% increase from baseline in FEV₁) from 5-minutes to 3-hours postdose on day 1 was evaluated using a logistic regression model with treatment groups, sex, and smoking status as fixed-effect factors and pre- and postbronchodilator FEV₁ at screening, age, and baseline FEV₁ as covariates. Odds ratios were estimated for each treatment group versus placebo. Change from baseline in TDI and SGRQ were analyzed using a MMRM as described for bronchodilation outcomes. A logistic random-effect model was used to analyze the number and percentage of patients who achieved a clinically meaningful improvement from baseline in SGRQ total score (decrease of ≥4 units) [19] or in TDI focal score (increase of ≥1 unit). Use of rescue medication was analyzed using averages of the daily diary values over the time periods between visits and were based on the change from baseline values. Daily COPD symptoms were analyzed by means of an MMRM adjusted for baseline, treatment, visit, sex, age, smoking status, and treatment-by-visit interaction. Safety results, summarized descriptively, were based on the safety population, defined as all randomized patients who took ≥1 dose of study medication.

Results

Patient disposition and baseline characteristics

A total of 1692 patients were randomized (Figure 2). Completion rates were highest with acclidinium/formoterol FDC 400/12 µg (80.5%) and acclidinium/formoterol FDC 400/6 µg (81.7%) and lowest with placebo (70.0%). Study discontinuations among randomized groups were most frequently due to AEs, protocol violation, and withdrawal of consent. A total of 5.9% of patients in the placebo group discontinued due to insufficient therapeutic response. Among the active treatment groups, discontinuations due to insufficient response were 2.9% for formoterol, 2.4% for acclidinium, and 1.5% and 1.2% for the acclidinium/formoterol FDC 400/12 µg and 400/6 µg groups.

Patient demographics and baseline characteristics were similar across groups (Table 1). The average patient age was 63.9 years, 53.1% were male, and 93.2% were white. Average postbronchodilator FEV₁% predicted at screening was 53.5% and baseline FEV₁ was 1.37 L. There were no notable differences in demographics between the ITT and safety populations.

Efficacy

1-hour postdose FEV₁

Treatment with both acclidinium/formoterol FDC doses resulted in clinically meaningful and significant improvements in lung function, measured by the change from baseline to week 24 in 1-hour postdose FEV₁ versus acclidinium monotherapy (coprimary endpoint), with least squares (LS) mean treatment differences of 108 mL (acclidinium/formoterol FDC 400/12 µg) and 87 mL (acclidinium/formoterol FDC 400/6 µg) (Figure 3A, p < 0.0001). At all timepoints from




Figure 2 Patient disposition. *Study terminated by Sponsor; ACL400/FOR12 FDC, fixed-dose combination of acclidinium 400 µg and formoterol 12 µg; ACL400/FOR6 FDC, fixed-dose combination of acclidinium 400 µg and formoterol 6 µg; COPD, chronic obstructive pulmonary disease; ITT, intention-to-treat.

Table 1 Demographic and baseline characteristics^a

Characteristics, mean (SD) ^b	PBO (n = 332)	ACL400/FOR12 FDC (n = 335)	ACL400/FOR6 FDC (n = 333)	ACL 400 (n = 337)	FOR 12 (n = 332)
Age, years	63.5 (8.9)	64.2 (8.9)	63.9 (9.2)	64.4 (8.7)	63.7 (8.7)
Male, n (%)	175 (52.7)	168 (50.1)	187 (56.2)	188 (55.8)	169 (50.9)
White, n (%)	317 (95.5)	305 (91.0)	309 (92.8)	314 (93.2)	311 (93.7)
Current smoker, n (%)	169 (50.9)	173 (51.6)	176 (52.9)	171 (50.7)	171 (51.5)
Smoking history, pack-years	53.3 (28.5)	53.3 (27.2)	52.1 (25.8)	52.0 (26.1)	52.5 (23.7)
Prebronchodilator FEV ₁ , L	1.35 (0.54)	1.34 (0.53)	1.40 (0.54)	1.34 (0.53)	1.37 (0.52)
Postbronchodilator FEV ₁ , % of predicted	52.6 (13.3)	53.2 (13.4)	54.7 (12.9)	53.0 (13.3)	53.9 (13.1)
Bronchial reversibility, %	18.4 (15.2)	17.2 (14.6)	17.7 (15.0)	19.1 (16.5)	17.3 (14.7)
COPD severity, n (%) ^c					
Moderate	177 (53.3)	189 (56.4)	203 (61.0)	184 (54.6)	197 (59.3)
Severe	150 (45.2)	142 (42.4)	127 (38.1)	147 (43.6)	131 (39.5)
Baseline efficacy variables ^d					
SGRQ total score	45.3 (17.9)	47.6 (16.9)	46.2 (17.9)	45.2 (17.8)	45.8 (17.9)
BDI focal score	6.4 (2.4)	6.2 (2.1)	6.5 (2.2)	6.5 (2.3)	6.3 (2.3)
Rescue medication use, puffs/day	4.2 (3.9)	4.5 (3.7)	4.0 (3.3)	4.0 (3.4)	4.3 (3.7)
EXACT-RS score	11.03 (5.84)	11.89 (6.51)	11.46 (6.25)	11.27 (6.33)	11.40 (6.57)
NISCI score	0.95 (0.63)	1.10 (0.70)	0.99 (0.69)	1.00 (0.70)	0.99 (0.71)
EMSCI score	1.07 (0.58)	1.19 (0.63)	1.15 (0.64)	1.13 (0.65)	1.13 (0.66)

^aFor the safety population, unless indicated otherwise; ^bAll results reported as mean values with standard deviations, unless indicated otherwise; ^cCOPD severity based on GOLD 2011 update guidelines [32]. A small (<2%) portion of the population (not shown here) were diagnosed as having mild or very severe COPD at baseline; ^dFor the intention-to-treat population: PBO, n = 331; ACL400/FOR12 FDC, n = 335; ACL400/FOR6 FDC, n = 333; ACL 400, n = 337; FOR 12, n = 332; Total, N = 1669.

ACL 400, acclidinium 400 µg; ACL400/FOR12 FDC, fixed-dose combination of acclidinium 400 µg and formoterol 12 µg; ACL400/FOR6 FDC, fixed-dose combination of acclidinium 400 µg and formoterol 6 µg; BDI, Baseline Dyspnea Index; COPD, chronic obstructive pulmonary disease; FEV₁, forced expiratory volume in 1 second; FOR 12, formoterol 12 µg; SGRQ, St. George's Respiratory Questionnaire; PBO, placebo; SD, standard deviation.

the first dose, treatment with either acclidinium/formoterol FDC 400/12 µg or acclidinium/formoterol FDC 400/6 µg resulted in significant improvements from baseline in 1-hour postdose FEV₁ compared with acclidinium, formoterol, and placebo (Figure 3B; $p < 0.01$ for all). At all timepoints, both monotherapies resulted in significantly greater improvements from baseline compared with placebo ($p < 0.0001$ for all). A numerically greater change from baseline in 1-hour postdose FEV₁ was evident for acclidinium/formoterol FDC 400/12 µg compared with acclidinium/formoterol FDC 400/6 µg at all timepoints, including 24 weeks, though the improvements did not reach statistical significance except at week 4 ($p < 0.05$).

Trough FEV₁


Treatment with acclidinium/formoterol FDC 400/12 µg significantly improved morning predose (trough) FEV₁ from baseline compared with formoterol at week 24 (coprimary endpoint), with an LS mean difference of 45 mL (Figure 4A, $p = 0.01$); treatment with acclidinium/formoterol FDC 400/6 µg resulted in a numerically greater improvement from baseline versus formoterol at study end (LS mean treatment difference, 26 mL;

$p = 0.133$). Significant improvements from baseline in trough FEV₁ were observed with acclidinium/formoterol FDC 400/12 µg compared with either monotherapy at all timepoints ($p < 0.05$ for all) except week 18 and 24 versus acclidinium (Figure 4B). At various timepoints throughout the study, both FDCs improved trough FEV₁ from baseline versus one or both monotherapies. Compared with placebo, both acclidinium/formoterol FDCs and the monotherapies significantly improved trough FEV₁ from baseline at all timepoints ($p < 0.0001$ for all). At all timepoints throughout the study, numerically greater improvements from baseline were observed in trough FEV₁ for the acclidinium/formoterol FDC 400/12 µg versus acclidinium/formoterol FDC 400/6 µg dose.


Onset of bronchodilation

Treatment with either acclidinium/formoterol FDC resulted in rapid bronchodilation, with significant improvements in FEV₁ over acclidinium and placebo observed within 5 minutes of the morning dose on day 1 (Figure 5A; both $p < 0.0001$). At week 24, FEV₁ results over the first 3 hours postdose were similar to those observed on day 1 (Figure 5B).

A Week 24



B By Study Visit



*At day 1 and day 4, $p < 0.05$ for all treatment groups versus placebo and $p < 0.05$ for both FDC groups versus acclidinium and formoterol

Figure 3 Mean changes from baseline in 1-hour morning postdose FEV₁ (A) at week 24 (coprimary endpoint) and (B) over time across duration of study. Analyses were based on a mixed-model for repeated measures. All active treatment groups were significant versus placebo ($p < 0.0001$) at all study visits. * $p < 0.05$ versus placebo; § $p < 0.05$ versus acclidinium, formoterol, and placebo. ACL400/FOR12 FDC, fixed-dose combination of acclidinium 400 µg and formoterol 12 µg; ACL400/FOR6 FDC, fixed-dose combination of acclidinium 400 µg and formoterol 6 µg; D1, day 1; D4, day 4; FEV₁, forced expiratory volume in 1 second; LS, least squares.

A significantly greater percentage of patients in the acclidinium/formoterol FDC 400/12 µg (26.3%), acclidinium/formoterol FDC 400/6 µg (23.1%), and formoterol (28.3%) groups achieved onset of action—defined as >15% increase from baseline in FEV₁—at 5 minutes postdose on day 1 than patients treated with acclidinium (6.5%; $p < 0.0001$ for both FDCs versus acclidinium, based on odds ratios) or placebo (2.1%; $p < 0.01$ all active treatment).

Peak FEV₁

Compared to monotherapy, treatment with either acclidinium/formoterol FDC resulted in sustained improvements in lung function over the 24-week study, with significant changes from baseline in peak FEV₁ at day 1 and week 24 ($p < 0.0001$ all comparisons). Compared to placebo, significant improvements in peak FEV₁ from baseline were observed with both acclidinium/formoterol FDCs at day 1 and week 24, with LS mean treatment differences of




Figure 4 Mean changes from baseline in morning predose (trough) FEV₁ (A) at week 24 (coprimary endpoint) and (B) over time across duration of study. Analyses were based on a mixed-model for repeated measures. *p < 0.05 versus placebo; †p < 0.05 versus formoterol and placebo; ‡p < 0.05 versus acclidinium, formoterol, and placebo; §p < 0.05 versus acclidinium, formoterol, and placebo. ACL400/FOR12 FDC, fixed-dose combination of acclidinium 400 µg and formoterol 12 µg; ACL400/FOR6 FDC, fixed-dose combination of acclidinium 400 µg and formoterol 6 µg; FEV₁, forced expiratory volume in 1 second; LS, least squares.

216 mL and 208 mL (day 1; acclidinium/formoterol FDC 400/12 µg and acclidinium/formoterol FDC 400/6 µg, p < 0.0001) and 285 mL and 259 mL (week 24; p < 0.0001 all comparisons). Changes from baseline in peak FEV₁ with acclidinium/formoterol FDC 400/12 µg were numerically

greater than those with acclidinium/formoterol FDC 400/6 µg at day 1 and week 24.

Maximal bronchodilation over placebo was achieved at 3 hours postdose on day 1 with acclidinium/formoterol FDC 400/12 µg and acclidinium/formoterol FDC 400/6 µg




Figure 5 Mean changes from baseline in FEV₁ 0–3 hours (A) on day 1 and (B) at week 24. Analyses were based on a mixed-model for repeated measures. *p < 0.05 versus placebo; †p < 0.05 versus acclidinium and placebo; §p < 0.05 versus acclidinium, formoterol, and placebo; ¶p < 0.05 versus acclidinium/formoterol FDC 400/6 and placebo. No significant differences between the two FDCs at any timepoint. ACL400/FOR12 FDC, fixed-dose combination of acclidinium 400 µg and formoterol 12 µg; ACL400/FOR6 FDC, fixed-dose combination of acclidinium 400 µg and formoterol 6 µg; FEV₁, forced expiratory volume in 1 second; LS, least squares.

(258 and 255 mL, respectively), similar to the values observed at week 24 (298 and 264 mL; all $p < 0.0001$ versus placebo). Significantly greater improvements in peak FEV₁ were observed on day 1 and week 24 in patients treated with either monotherapy compared with placebo (LS mean difference for acclidinium and formoterol: day 1, 165 mL and 154 mL; week 24, 174 mL and 182 mL; $p < 0.0001$ all comparisons).

12-hour serial spirometry substudy

In a subset of ITT patients (N = 270) who participated in a 12-hour serial spirometry substudy, statistically significant changes from baseline in FEV₁ over placebo were observed at most timepoints for those treated with either acclidinium/formoterol FDC; results for both acclidinium/formoterol FDCs were numerically greater than the monotherapies (Additional file 1: Figure S1). Data from the serial spirometry substudy support the results observed for the entire ITT population and substantiates the BID dosing regimen of the acclidinium/formoterol FDCs, as demonstrated by the FEV₁ values over the entire dosing interval (Additional file 1: Figure S1).

Breathlessness

At week 24, significant improvements in TDI focal scores were achieved with the acclidinium/formoterol FDCs compared with placebo (secondary endpoint; $p < 0.0001$), as well as with either acclidinium or formoterol ($p \leq 0.01$ for both versus placebo; Figure 6A). Treatment with the acclidinium/formoterol FDCs resulted in numerically greater improvements in TDI focal scores compared to either

monotherapy. At all other study visits, significantly greater improvements in TDI focal scores were observed with acclidinium/formoterol FDC 400/12 µg versus formoterol ($p < 0.01$); improvements in TDI focal scores were similar between acclidinium/formoterol FDC 400/12 µg and acclidinium/formoterol FDC 400/6 µg.

At week 24, all active treatments reached the MCID of 1-unit improvement from baseline. The percentage of patients who reached the MCID of ≥ 1 -unit improvement from baseline in TDI focal score was greater in either acclidinium/formoterol FDC group versus placebo ($p < 0.0001$ based on odds ratios). Treatment with either monotherapy also resulted in significantly greater percentages of patients who achieved the MCID versus placebo at week 24 ($p < 0.01$), though greater odds ratios were observed with the FDCs compared to either monotherapy (Figure 6B). At week 24, average increases in TDI focal scores beyond the MCID of 1-unit improvement over placebo (considered a more stringent criteria than improvements over baseline) were observed in patients treated with either acclidinium/formoterol FDC ($p < 0.0001$). Both monotherapies neared the 1-unit improvement over placebo at week 24, with changes from baseline of 0.98 and 0.94 for acclidinium and formoterol, respectively. All active treatment arms resulted in significantly greater percentages of responders versus placebo throughout the study period (Figure 6C).

Health status

At week 24, significant improvements in SGRQ total scores from baseline were observed with the acclidinium/




Figure 6 (See legend on next page.)

(See figure on previous page.)

Figure 6 Improvements in TDI focal score as assessed by (A) mean changes from baseline at week 24, (B) percentage of patients who responded at week 24, and (C) percentage of patients who responded over time. Mean changes were analyzed using a mixed-model for repeated measures. Responders were defined as patients who had a TDI focal score improvements of ≥ 1 unit; ORs based on a logistic random effect model for active treatment versus placebo. * $p < 0.01$ versus placebo; ** $p \leq 0.001$ versus placebo; † $p < 0.05$ versus acclidinium and placebo; ‡ $p < 0.05$ versus formoterol and placebo. ACL400/FOR12 FDC, fixed-dose combination of acclidinium 400 μg and formoterol 12 μg ; ACL400/FOR6 FDC, fixed-dose combination of acclidinium 400 μg and formoterol 6 μg ; LS, least squares; OR, odds ratio; TDI, Transition Dyspnea Index.

formoterol FDCs and the monotherapies versus placebo (secondary endpoint, $p < 0.05$; Figure 7A). At all timepoints, a significantly greater percentage of responders (patients achieving ≥ 4 -unit improvement from baseline in SGRQ total score) were observed with either acclidinium/formoterol FDC versus placebo, including at study end (Figure 7B, both $p < 0.01$).

At week 24, mean differences in SGRQ total score over placebo (again, a more rigorous criteria than over baseline) exceeded the MCID of 4 units in patients treated with acclidinium/formoterol FDC 400/12 μg or acclidinium monotherapy (week 24; $p < 0.001$). Compared with placebo, treatment with either acclidinium or formoterol resulted in a significantly greater percentage of responders at weeks 4 and 24, while treatment with either acclidinium/formoterol FDC resulted in significantly greater percentages of responders at all study weeks (Figure 7C; all comparisons $p < 0.05$ versus placebo).

Rescue medication use

Compared with placebo, significant reductions in the change from baseline in overall total daily rescue medication use over 24 weeks were observed in each active treatment group ($p < 0.0001$). A numerically greater magnitude of effect was observed in patients treated with the acclidinium/formoterol FDCs compared to either monotherapy (-1.11 and -1.10 puffs per day for acclidinium/formoterol FDC 400/12 μg and 400/6 μg versus -0.68 acclidinium and -0.90 formoterol). Improvements from baseline in overall total daily use of rescue medication were significantly greater for both acclidinium/formoterol FDCs versus acclidinium alone ($p < 0.01$).

EXACT-RS

Over 24-weeks, significant improvements in overall average daily EXACT-Respiratory Symptoms scores were observed with both FDCs and the monotherapies compared with placebo (Figure 8A; $p < 0.01$). The changes from baseline in overall average daily E-RS scores were numerically improved for acclidinium/formoterol FDC 400/12 μg and significantly improved for acclidinium/formoterol FDC 400/6 μg versus either monotherapy ($p < 0.05$). For the change from baseline in E-RS total score, significant improvements from baseline were observed for all active treatment groups over placebo at all study visits ($p < 0.05$ for all). No consistently significant

improvements were observed for either of the FDCs versus the monotherapies across visits, though both FDCs showed significant improvements compared with acclidinium and/or formoterol intermittently during the study. At all assessments, the acclidinium/formoterol FDC 400/6 μg dose resulted in numerically greater improvements than the acclidinium/formoterol FDC 400/12 μg dose.

Nighttime symptoms of COPD

Treatment with either acclidinium/formoterol FDC resulted in significant improvements versus placebo in overall nighttime symptom severity, measured by the NiSCI, at all study visits including study end (Figure 8B; $p < 0.01$ versus placebo). While treatment with either acclidinium or formoterol monotherapies significantly improved nighttime symptom severity over placebo at weeks 4 and 18 (both $p < 0.05$), statistical significance was not met at week 24. Patients in the acclidinium/formoterol FDC treatment groups reported greater reductions in overall nighttime COPD symptom severity versus either monotherapy at week 24, with results reaching statistical significance for the acclidinium/formoterol FDC 400/6 μg versus acclidinium (Figure 8B; $p < 0.05$). At all other timepoints (weeks 4, 12, and 18), both acclidinium/formoterol FDCs resulted in significant reductions in overall nighttime symptom severity versus acclidinium ($p < 0.05$). Significant improvements versus formoterol were observed for the acclidinium/formoterol FDC 400/12 μg dose at weeks 4 and 18, while the acclidinium/formoterol FDC 400/6 μg resulted in significant improvements in this comparison at weeks 12 and 18 (all $p < 0.05$). Numerically greater improvements were observed with the FDC 400/12 dose versus the FDC 400/6 dose at week 4.

Early morning symptoms of COPD

The average rating for overall early morning COPD symptom severity via the EMSCI was significantly improved for the acclidinium/formoterol FDCs compared with placebo at all timepoints including study end (Figure 8C; $p < 0.01$ for all). Neither monotherapy treatment resulted in improvements in symptom severity over placebo at any visit with the exception of formoterol at week 4 ($p < 0.01$). At week 24, the average rating for overall early morning COPD symptom severity via the EMSCI was significantly improved for both acclidinium/formoterol FDCs versus acclidinium ($p < 0.05$), but not versus formoterol. For all




Figure 7 (See legend on next page.)

(See figure on previous page.)

Figure 7 Improvements in SGRQ total score as assessed by (A) mean changes from baseline at week 24, (B) percentage of patients who responded at week 24, and (C) percentage of patients who responded over time. Mean changes were analyzed using a mixed-model for repeated measures. Responders were defined as patients who had a ≥ 4 -point improvement from baseline in SGRQ total score, with ORs based on a logistic random effect model for active treatment versus placebo. * $p < 0.05$ versus placebo; ** $p \leq 0.001$ versus placebo. ACL400/FOR12 FDC, fixed-dose combination of acclidinium 400 μg and formoterol 12 μg ; ACL400/FOR6 FDC, fixed-dose combination of acclidinium 400 μg and formoterol 6 μg ; LS, least squares; OR, odds ratio; SGRQ, St. George's Respiratory Questionnaire.

other timepoints, both acclidinium/formoterol FDCs significantly reduced early morning symptom severity compared with either monotherapy ($p \leq 0.01$ for all), except at week 4 for acclidinium/formoterol FDC 400/12 μg versus formoterol. Improvements observed between the acclidinium/formoterol FDCs were similar throughout the study.

Safety

The overall incidence of treatment-emergent AEs (TEAEs) with acclidinium/formoterol FDCs was similar to those of acclidinium and numerically greater than formoterol, with no apparent dose-related trends between the higher and lower FDC doses. The most commonly reported TEAEs ($\geq 5\%$ of patients in any treatment group) were cough and nasopharyngitis (Table 2). The majority of TEAEs were mild or moderate in severity and were considered unrelated to treatment by trial investigators. The incidences of AEs that led to discontinuation were comparable between acclidinium/formoterol FDC 400/12 μg (6.3%), acclidinium/formoterol FDC 400/6 μg (6.6%), and placebo (6.3%), and slightly lower in the acclidinium (4.7%) and formoterol (4.2%) groups. The AE most commonly associated with discontinuation was dyspnea, reported mostly in the placebo group (0.9% placebo versus $\leq 0.6\%$ in active treatment arms).

Of the class-related AEs that may occur due to both anticholinergic and β_2 -agonist mechanisms, only urinary tract infection occurred in $>2\%$ of patients in any treatment group (Table 2). The most common ($>2\%$ and $>$ placebo) potential anticholinergic AEs that occurred with acclidinium/formoterol FDC 400/12 μg versus acclidinium alone were dry mouth (2.4% versus 0.6%) and oropharyngeal pain (2.1% versus 1.2%). The most common ($>2\%$ and $>$ placebo) β_2 -agonist AEs with acclidinium/formoterol FDC 400/12 μg versus formoterol alone were cough (5.1% versus 3.0%), headache (4.8% versus 3.6%), and muscle spasm (2.7% versus 1.8%).

The overall incidence of serious AEs (SAEs) was low and numerically higher in all active treatment arms compared with placebo (5.7% acclidinium/formoterol FDC 400/12 μg , 5.4% acclidinium/formoterol FDC 400/6 μg , 5.0% acclidinium, 4.5% formoterol, and 3.6% placebo). Pneumonia, the most common SAE, was reported by no more than 3 (0.9%) patients in any randomized group (2 patients in the acclidinium/formoterol FDC 400/12 μg group, 1 in

acclidinium/formoterol FDC 400/6 μg , 1 in acclidinium, 3 in formoterol, and 3 in placebo); none of the reported cases of pneumonia were considered treatment related. Overall, 3 patients experienced an SAE that was considered related to treatment (1 each in the placebo [atrial fibrillation], acclidinium/formoterol FDC 400/12 μg [pneumonitis], and formoterol groups [atrial fibrillation], with only the placebo-treated patient discontinuing due to the SAE).

The number of Major Adverse Cardiac Events (MACEs), based on blinded adjudication, TEAEs and SAEs, were infrequent and occurred at similar incidences across all treatment groups. All adjudicated MACEs were SAEs with the exception of 1 report of moderate nonfatal stroke in the placebo group. Based on adjudicated SAEs, a total of 12 MACEs were reported for 12 patients. MACEs based on adjudicated SAEs were reported in 2 (0.6%) and 4 (1.2%) patients in the acclidinium/formoterol FDC 400/12 μg and 400/6 μg treatment groups. A total of 2 (0.6%) patients in the placebo group, 1 (0.3%) patient in the acclidinium group, and 3 (0.9%) patients in the formoterol group reported MACEs. All MACEs were considered unrelated to treatment.

A total of 5 deaths occurred during the treatment period or within 30 days of the last dose of investigational product, none of which were considered related to treatment. One death occurred in the acclidinium/formoterol FDC 400/12 μg group, 3 in the acclidinium group, and 1 in the formoterol group. Three of these deaths (1 each in the acclidinium/formoterol FDC 400/12 μg , acclidinium, and formoterol groups) were adjudicated as CV deaths (etiology unknown). The other two deaths, both occurring in the acclidinium group, were due to esophageal adenocarcinoma and gastrointestinal necrosis.

Mean changes from baseline in clinical laboratory parameters, vital signs, and ECGs were small and of no clinical relevance. Holter monitoring did not show any findings of an ECG effect for patients in any group, and no differences were observed between the treatment arms.

Discussion

An FDC comprising bronchodilators with complementary mechanisms of action may improve lung function, while offering patients the convenience of drug delivery via a single device without increasing the risk for adverse




Figure 8 (See legend on next page.)

(See figure on previous page.)

Figure 8 Mean changes from baseline to week 24 in (A) E-RS overall average daily score over the study period, (B) nighttime symptom severity, and (C) early morning symptom severity. Parenthetical values are the percent changes from baseline for the specified group. The E-RS analysis was conducted using the ITT exacerbation population, defined as all randomized patients who received ≥ 1 dose of double-blind study drug; the analyses of nighttime and early morning symptom severity were conducted using the general ITT population. For all outcomes, mean changes were analyzed using a mixed-model for repeated measures. * $p < 0.05$ versus placebo; † $p < 0.05$ versus acclidinium and placebo; ‡ $p < 0.05$ versus acclidinium, formoterol, and placebo. ACL400/FOR12 FDC, fixed-dose combination of acclidinium 400 μg and formoterol 12 μg ; ACL400/FOR6 FDC, fixed-dose combination of acclidinium 400 μg and formoterol 6 μg ; EMSCI, early morning symptoms of COPD instrument; E-RS, EXACT respiratory symptoms; ITT, intention-to-treat; LS, least square; NiSCI, nighttime symptoms of COPD instrument.

events [20]. Though the interaction between LAMAs and LABAs has not been definitively determined, LABAs have been shown to enhance the bronchodilatory effect of LAMAs through a decrease in acetylcholine transmission that leads to a reduction in bronchoconstriction, while LAMAs amplify the effect of LABAs by blocking the muscarinic receptors targeted by acetylcholine, resulting in further bronchodilation [3,21,22]. Thus, a fixed-dose

combination of a LAMA and LABA is an important therapeutic option, providing patients with more convenient drug delivery and the potential for improved compliance.

In this trial, treatment with the LAMA/LABA fixed dose combination of acclidinium/formoterol FDC 400/12 μg for 24 weeks resulted in statistically significant and clinically meaningful improvements for the coprimary measures of lung function: 1-hour morning postdose FEV₁ versus

Table 2 Treatment-emergent adverse events^a ($\geq 2\%$ in any treatment group)

	PBO (n = 332)	ACL400/FOR12 FDC (n = 335)	ACL400/FOR6 FDC (n = 333)	ACL400 (n = 337)	FOR 12 (n = 332)
Patients with ≥ 1 TEAE, n (%)	181 (54.5)	215 (64.2)	203 (61.0)	210 (62.3)	189 (56.9)
TEAEs by preferred term, n (%)					
Cough ^b	12 (3.6)	17 (5.1)	13 (3.9)	7 (2.1)	10 (3.0)
Headache ^b	11 (3.3)	16 (4.8)	14 (4.2)	13 (3.9)	12 (3.6)
Nasopharyngitis	12 (3.6)	16 (4.8)	17 (5.1)	12 (3.9)	22 (6.6)
Urinary tract infection ^{b,c}	10 (3.0)	15 (4.5)	7 (2.1)	11 (3.3)	9 (2.7)
Back pain	9 (2.7)	10 (3.0)	5 (1.5)	4 (1.2)	6 (1.8)
Upper respiratory tract infection	5 (1.5)	10 (3.0)	13 (3.9)	11 (3.3)	9 (2.7)
Diarrhea	8 (2.4)	9 (2.7)	10 (3.0)	9 (2.7)	6 (1.8)
Muscle spasms ^b	3 (0.9)	9 (2.7)	4 (1.2)	2 (0.6)	6 (1.8)
Sinusitis	7 (2.1)	9 (2.7)	8 (2.4)	12 (3.6)	6 (1.8)
Dry mouth ^c	1 (0.3)	8 (2.4)	5 (1.5)	2 (0.6)	3 (0.9)
Tooth abscess	2 (0.6)	8 (2.4)	2 (0.6)	2 (0.6)	0
Musculoskeletal pain	2 (0.6)	7 (2.1)	0	2 (0.6)	3 (0.9)
Oropharyngeal pain	10 (3.0)	7 (2.1)	6 (1.8)	4 (1.2)	6 (1.8)
Dizziness	7 (2.1)	6 (1.8)	4 (1.2)	5 (1.5)	8 (2.4)
Insomnia ^b	2 (0.6)	6 (1.8)	3 (0.9)	3 (0.9)	9 (2.7)
Dyspnea	6 (1.8)	5 (1.5)	11 (3.3)	6 (1.8)	3 (0.9)
Nausea	4 (1.2)	5 (1.5)	15 (4.5)	12 (3.6)	14 (4.2)
Hypertension ^b	6 (1.8)	4 (1.2)	9 (2.7)	10 (3.0)	9 (2.7)
Constipation ^{b,c}	6 (1.8)	3 (0.9)	4 (1.2)	7 (2.1)	4 (1.2)
Pain in extremity	0	3 (0.9)	3 (0.9)	7 (2.1)	2 (0.6)
Vomiting	2 (0.6)	3 (0.9)	7 (2.1)	5 (1.5)	3 (0.9)
Fatigue	8 (2.4)	2 (0.6)	6 (1.8)	4 (1.2)	7 (2.1)
Gastroenteritis viral	8 (2.4)	2 (0.6)	5 (1.5)	3 (0.9)	2 (0.6)

^aPer protocol exacerbations of COPD were not considered an *a priori* safety outcome and are therefore not included within the safety results; ^bPotential β_2 -agonist TEAE; ^cPotential anticholinergic TEAE.

ACL 400, acclidinium 400 μg ; ACL400/FOR12 FDC, fixed-dose combination of acclidinium 400 μg and formoterol 12 μg ; ACL400/FOR6 FDC, fixed-dose combination of acclidinium 400 μg and formoterol 6 μg ; PBO, placebo; TEAE, treatment-emergent adverse event.

acclidinium monotherapy (contribution of formoterol) and morning trough FEV₁ versus formoterol (contribution of acclidinium).

The coprimary endpoints in the AUGMENT COPD study reported here reflect FDA guidance regarding fixed-dose combination drugs (ie, each component of the fixed-dose combination must make a contribution to the claimed effects [23]). One aspect behind the rationale for combining acclidinium and formoterol for this FDC was the difference in time course for effective bronchodilation between the two drugs. Formoterol was expected to provide a rapid onset of action while the contribution of acclidinium was expected to occur over many hours (at trough) [11,24]. The trial was thus powered to detect differences in the prespecified coprimary endpoint comparisons: 1-hour morning postdose FEV₁ for the FDCs versus acclidinium (to observe the early contribution of formoterol) and trough FEV₁ for the FDCs versus formoterol (to observe the contribution of acclidinium over many hours). Any other comparisons for these outcomes were considered supportive in nature.

At study end, the acclidinium/formoterol 400/12 µg FDC provided an additional 45 mL in trough FEV₁ from baseline (contribution of acclidinium), while the contribution of formoterol to the FDC (acclidinium/formoterol FDC 400/12 µg versus acclidinium) was 28 mL, indicating that acclidinium provided greater bronchodilation. Results for trough FEV₁ over the course of the study support the endpoint observation that the contribution of formoterol as a component of the FDC was smaller than that of acclidinium. Additionally, trough FEV₁ values for both FDCs were numerically greater than acclidinium at all timepoints throughout the study, a result that is supportive of the observation that the FDCs provide greater bronchodilation than either monotherapy component alone.

Throughout the study, improvements in lung function with acclidinium/formoterol FDC 400/12 µg, which were numerically greater than those with acclidinium/formoterol FDC 400/6 µg, were generally similar to the results observed in a similarly designed study (ACLIFORM COPD) [25]. Results from this trial also demonstrate rapid bronchodilation with acclidinium/formoterol FDC treatment (within 5 minutes of dosing) that was sustained and clinically meaningful in patients with COPD. Both acclidinium/formoterol FDCs had safety profiles generally similar to that of each monotherapy, though there were a numerically greater percentage of FDC- and acclidinium-treated patients who experienced any AE compared with those treated with formoterol. The incidence of MACE was comparable among all active treatment groups. Together, these results indicate that treatment with a fixed-dose combination of acclidinium/formoterol achieves a level of bronchodilation greater than either monotherapy component and is well-

tolerated in patients with moderate to severe COPD. The therapeutic benefits on lung function derived from treatment with the acclidinium/formoterol FDCs exceeded the recommended MCID of 100 mL in 1-hour morning postdose FEV₁ versus placebo and were consistently significantly greater than those of the monotherapies. These improvements were observed from the first timepoint assessed until the end of the study, demonstrating sustained bronchodilation throughout 24 weeks of treatment.

Onset of bronchodilation (>15% increase from baseline in FEV₁) with acclidinium/formoterol FDC 400/12 µg was observed as early as 5 minutes after the first dose, similar to that of formoterol—a LABA known to have a fast onset of action [26]. The improved efficacy with the acclidinium/formoterol LAMA/LABA combination over the monotherapy components and placebo may be attributed to complementary pharmacodynamic profiles of these 2 bronchodilators: direct bronchodilation by the β₂-agonist, formoterol, provides rapid onset of action, while reduction in bronchoconstriction by the antimuscarinic, acclidinium, prolongs duration of bronchodilation [24,27]. As rapid onset of effect has been associated with better patient compliance [28,29], the onset of action observed with the acclidinium/formoterol FDCs may have a positive effect on medication adherence in clinical practice.

Although spirometric outcomes are important in assessing airflow obstruction in patients with COPD, clinical measures of health status have been shown to correlate better with symptoms such as breathlessness [30,31]—one of the most troublesome symptoms of the disease that often contributes to limitations in patients' activities [30-32]. Following 24 weeks of treatment, improvements in SGRQ total score exceeded the MCID over placebo in patients treated with either acclidinium/formoterol FDC 400/12 µg or acclidinium monotherapy. Patients treated with acclidinium/formoterol FDC 400/12 µg also experienced improvements in TDI focal score that exceeded the MCID over placebo. Compared with placebo, a significantly greater percentage of acclidinium/formoterol FDC 400/12 µg and 400/6 µg-treated patients reached the MCID for both SGRQ and TDI at all study visits. These results support the clinical benefit of acclidinium/formoterol FDCs in improving health status and in reducing breathlessness, important treatment goals for the effective management of COPD [32].

A recently published review of the applicability of MCIDs in COPD trials outlines numerous challenges when comparing combination therapies to monotherapy [33]. The authors indicate that improvements in various outcome measures with combination therapy over monotherapy should not be expected to exceed those of monotherapy over placebo or to produce a result that would reach an MCID. Further, the authors suggest that MCIDs or

responder rates derived from trials comparing a single active agent to placebo may not be applicable to combination therapy trials in which the comparison is to each monotherapy component. It is not surprising that the observed differences between monotherapy and placebo are often greater than the differences between combination therapy and the monotherapy components [34]. To describe the additional proportion of patients who may experience improvements at or above the MCID following the addition of one active treatment to another, the concept of a “minimum worthwhile incremental advantage” has been proposed [33]. In light of the caveats inherent in combination versus monotherapy trials, as well as the recognition that patients may experience advantages with combination therapy that are not readily measurable by certain outcome criteria, it is reasonable to conclude that the improvements in lung function and symptoms observed with the acclidinium/formoterol FDCs over each monotherapy in this trial may have clinical benefits for the moderate to severe COPD patient.

Due to the circadian nature of cholinergic tone, more impaired lung function is observed in the evening versus daytime in patients with COPD [35]. This in turn may be related to the prevalence of sleep disturbance in a majority of patients with COPD [36,37], as well as reports of nighttime and early morning being the worst times of day for COPD patients due to breathlessness and other symptoms [38]. Twice-daily acclidinium has been shown to significantly improve lung function at night compared with once-daily tiotropium [8], while other twice-daily COPD medications, including formoterol, reportedly improve nighttime symptoms [39-42]. In the trial reported here, acclidinium/formoterol FDCs significantly reduced both nighttime and early morning symptoms compared with placebo—measured by the newly developed NiSCI and EMSCI patient reported outcome measures—while treatment with the monotherapy components generally did not reach statistical significance in these outcomes. The disparity between nighttime symptoms outcomes with acclidinium monotherapy in this trial with those in a previously conducted study [43] could be due to the manner in which nighttime symptoms were evaluated as both the NiSCI and the EMSCI are currently undergoing empirical testing.

As the current study demonstrated that acclidinium/formoterol administered in the morning significantly improves bronchodilation as rapidly as 5 minutes postdose, the evening dose of this twice-daily treatment may also alleviate impaired airflow at night and reduce breathlessness, potentially providing the added benefit of improving COPD symptoms when they are at their worst. Further analyses are necessary to correlate the clinically meaningful treatment effect of the acclidinium/formoterol FDCs on lung function with the positive effects on COPD symptoms.

Conclusions

The spirometric and clinical outcomes from this study demonstrate the sustained and improved efficacy of a fixed-dose combination of acclidinium 400 µg/formoterol 12 µg over its monotherapy components. With a safety profile generally similar to the acclidinium and formoterol monotherapies, the results reported here support the use of an acclidinium/formoterol FDC as maintenance treatment for patients with moderate to severe COPD.

Additional file

Additional file 1: Table S1. Schedule of Evaluations. Figure S1.

Change from baseline in FEV₁ by timepoint at week 24. This analysis was conducted in a subset of patients from the ITT population who participated in the 12-hour serial spirometry substudy. ACL400/FOR12 FDC, fixed-dose combination of acclidinium 400 µg and formoterol 12 µg; ACL400/FOR6 FDC, fixed-dose combination of acclidinium 400 µg and formoterol 6 µg; FEV₁, forced expiratory volume in 1 second; ITT, intention-to-treat; LS, least square.

Abbreviations

AE: Adverse event; ACL: Acclidinium; BDI: Baseline dyspnea index; BID: Twice daily; COPD: Chronic obstructive pulmonary disease; CV: Cardiovascular; ECG: Electrocardiogram; EMSCI: Early morning symptoms of COPD instrument; EXACT-RS: EXAcerbations of Chronic pulmonary disease Tool – Respiratory Symptoms; FDC: Fixed-dose combination; FEV₁: Forced expiratory volume in 1 second; FOR: Formoterol; FVC: Forced vital capacity; ICS: Inhaled corticosteroids; ITT: Intention-to-treat; LABA: Long-acting β₂-agonist; LAMA: Long-acting muscarinic antagonist; LS: Least square; MACE: Major adverse cardiovascular events; MCID: Minimal clinically important difference; MedDRA: Medical dictionary for regulatory activities; MI: Myocardial infarction; MMRM: Mixed model for repeated measures; NiSCI: Nighttime Symptoms of COPD Instrument; SAE: Serious adverse event; SGRQ: St. George's respiratory questionnaire; TDI: Transition dyspnea index.

Competing interests

AD has received research, consulting, and lecturing fees from Forest Laboratories, GlaxoSmith Kline, Sepracor, Merck Canada, Schering Plough, Novartis Canada/USA, Altana, Boehringer Ingelheim Canada, Methapharm, Pfizer Canada, AstraZeneca, Skye Pharma, Ono Pharma, and Kos Pharmaceuticals. SR has served as a consultant or participated in advisory boards for ABIM, Able Associates, Adelphi Research, Almirall, APT, Aradigm, Argenta, AstraZeneca, BI (ACCP), Biostrategies, BoomCom, Britnall and Nicolini, Capital Research, Chiesi, Clinical Advisors, CommonHealth, Complete Medical Group, Consult Complete, COPDForum, DataMonitor, Decision Resources, Defined Health, Dey, Dunn Group, Easton Associates, Enterprise Analysis, Equinox, Forest, Fulcrum, Gerson Lehman, GSK, Guidepoint, Hoffman LaRoche, IMS, Informed, Inspire, Insyght, KOL Connection, Leerink Swan, M. Pankove, MDRx Financial, MedaCorp, Medimmune, Mpex, Novartis, Nycomed, Oriol, Otsuka, Pearl, Pennside Partners, Pfizer, Pharma Ventures, Pharmaxis, Pick Research, Prescott, Price Waterhouse, Propagate, Pulmatrix, Pulmonary Reviews, Quadrant, Reckner Associates, Recruiting Resource, Reviews and Trends in COPD/Convergent Health Solutions, Roche, Sacoor, Schering, Schlesinger Medical, Scimed, Smith Research, Sudler and Hennessey, Talecris, Theravance, UBC, Uptake Medical, and Vantage Point. He has received lecture fees from AAAAI, Am Col Osteopathic Physicians, Asan Medical Center, ATS, AstraZeneca, California Soc Allergy, Convergent Health Solutions for Reviews and Trends in COPD, COPDFoundation, Creative Educational Concepts, Dey, Duke, France Foundation, Information TV, University of California-Los Angeles, Network for Continuing Education, Novartis, Nycomed, Otsuka, Pfizer, Sarasota Mem Hospital, Spanish Thoracic Society, University of Washington, University of Alabama-Birmingham, University of Pittsburgh, University of British Columbia, University of California-Davis, VA Sioux Falls. He has received industry-sponsored grants from AstraZeneca, Biomarc, Centocor, GlaxoSmithKline, Mpex, Nabi, Novartis, Otsuka, and Pfizer. Peter M.A. Calverley has given presentations at symposia sponsored by Astra

Zeneca, Boehringer, GlaxoSmithKline, and Nycomed, and has received fees for advising Astra Zeneca, Boehringer, GlaxoSmithKline, Novartis, and Nycomed. Shawn X. Sun, Stavros Tourkodimitris, and Paul Rowe are employees of Forest Research Institute, Inc. Udo M. Goehring and Dirk Bredenbröcker are employees of Takeda Pharmaceuticals International GmbH. EK has served on advisory boards, speaker panels, or received travel reimbursement with AstraZeneca, Forest, Ironwood, Merck, Mylan, Novartis, Pearl, Pfizer, Sanofi Aventis, Sunovion, Targacept, and Theravance; EK has also conducted multicenter clinical research trials for approximately 70 pharmaceutical companies, including Forest Laboratories and Almirall, S.A. VM is an employee of Forest Laboratories, LLC. AL is an employee of Almirall, S.A. CC was an employee of Forest Laboratories, LLC at the time the study was conducted.

This study was funded by Forest Laboratories LLC, a subsidiary of Actavis plc, and by Almirall, S.A. The sponsors did not place any restriction on authors about the statements made in the final paper.

Authors' contributions

AD and EK participated in the study and contributed to the analysis and interpretation of data. SR, VM, AL, and CC contributed to the design of the study, analyses, and interpretation of data. All authors were involved in the creation and critical review of the manuscript and provided approval of the final manuscript.

Acknowledgements

The authors would like to thank the AUGMENT COPD study investigators. Editorial assistance and technical writing was provided by Debika Chatterjee, PhD and Kristen A. Andersen, PhD of Prescott Medical Communications Group (Chicago, IL, USA), funded by Forest Laboratories, LLC, a subsidiary of Actavis plc (New York, NY, USA).

Author details

¹University of Toronto, Toronto, Canada. ²University of Nebraska Medical Center, Omaha, NE, USA. ³Clinical Research Institute, Medford, OR, USA. ⁴Forest Research Institute, Jersey City, NJ, USA. ⁵R&D Centre, Almirall, Barcelona, Spain.

Received: 3 June 2014 Accepted: 30 September 2014

Published online: 14 October 2014

References

- Global Initiative for Chronic Obstructive Lung Disease (GOLD): **Global strategy for the diagnosis, management and prevention of COPD (2014 update)**. [http://www.goldcopd.org/]
- Rabe KF, Timmer W, Sagkriotis A, Viel K: **Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD**. *Chest* 2008, **134**:255–262.
- van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJ: **Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD**. *Eur Respir J* 2005, **26**:214–222.
- Wang J, Jin D, Zuo P, Wang T, Xu Y, Xiong W: **Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis**. *Respirology* 2011, **16**:350–358.
- Mahler DA, D'Urzo A, Bateman ED, Ozkan SA, White T, Peckitt C, Lassen C, Kramer B, Intrust study investigators: **Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison**. *Thorax* 2012, **67**:781–788.
- van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJ: **Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD**. *Chest* 2006, **129**:509–517.
- D'Urzo A, Kerwin E, Rennard S, He T, Gil EG, Caracta C: **One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily acclidinium bromide in patients with COPD**. *COPD* 2013, **10**:500–510.
- Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten AM, Falques M, Caracta CF, Garcia Gil E: **Efficacy of acclidinium bromide 400 µg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD**. *Chest* 2012, **141**:745–752.
- Gelb AF, Tashkin DP, Make BJ, Zhong X, Garcia Gil E, Caracta C: **Long-term safety and efficacy of twice-daily acclidinium bromide in patients with COPD**. *Respir Med* 2013, **107**:1957–1965.
- Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R, Caracta C, Garcia Gil E: **Efficacy and safety of twice-daily acclidinium bromide in COPD patients: the ATAIN study**. *Eur Respir J* 2012, **40**:830–836.
- Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF: **Efficacy and safety of a 12-week treatment with twice-daily acclidinium bromide in COPD patients (ACCORD COPD I)**. *COPD* 2012, **9**:90–101.
- Foradil prescribing information**. [http://www.merck.com/product/usa/pi_circulars/f/foradil/foradil_pi.pdf]
- Maltais F, Celli B, Casaburi R, Porszasz J, Jarreta D, Seoane B, Caracta C: **Acclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD**. *Respir Med* 2011, **105**:580–587.
- Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P: **Standardisation of spirometry**. *Eur Respir J* 2005, **26**:319–338.
- Leidy NK, Murray LT: **Patient-reported outcome (PRO) measures for clinical trials of COPD: the EXACT and E-RS**. *COPD* 2013, **10**:393–398.
- Hareendran A, Palsgrove A, Mocarski M, Schaefer M, Setyawan J, Carson R, Make BJ: **The development of a patient-reported outcome measure for assessing nighttime symptoms of chronic obstructive pulmonary disease**. *Health Qual Life Outcomes* 2013, **11**:104–112.
- Mocarski M, Hareendran A, Jen M-H, Zaiser E, Make BJ: **Evaluation of the Psychometric Properties of the Nighttime Symptoms of COPD Instrument (NISCI) [abstract]**. *Am J Respir Crit Care Med* 2014, **189**:A5843.
- Mocarski M, Hareendran A, Jen M-H, Zaiser E, Make BJ: **Evaluation of the Psychometric Properties of the Early Morning Symptoms of COPD Instrument (EMSCI) [abstract]**. *Value Health* 2014, **17**(3):A179.
- Jones PW: **St. George's Respiratory Questionnaire: MCID**. *COPD* 2005, **2**:75–79.
- Yu AP, Guerin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J: **Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers**. *J Med Econ* 2011, **14**:486–496.
- Cazzola M, Molimard M: **The scientific rationale for combining long-acting beta₂-agonists and muscarinic antagonists in COPD**. *Pulm Pharmacol Ther* 2010, **23**:257–267.
- Cazzola M, Di Marco F, Santus P, Boveri B, Verga M, Matera MG, Centanni S: **The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD**. *Pulm Pharmacol Ther* 2004, **17**:35–39.
- FDA: **Code of Federal Regulations (CFR Section 300.50): Fixed-combination prescription drugs for humans**. [http://www.gpo.gov/fdsys/pkg/CFR-2011-title21-vol5/pdf/CFR-2011-title21-vol5-sec300-50.pdf]
- Benhamou D, Cuvelier A, Muir JF, Leclerc V, Le Gros V, Kottakis J, Bourdeix I: **Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk)**. *Respir Med* 2001, **95**:817–821.
- Singh D, Jones PW, Bateman ED, Korn S, Serra C, Molins E, Caracta C, Garcia Gil E: **Evaluation of the efficacy and safety of two doses of acclidinium and formoterol in fixed-dose combination in patients with COPD: the ACLIFORM study [abstract]**. *Chest* 2014, **145**(3):Suppl 375A.
- Anderson G: **Formoterol: pharmacology, molecular basis of agonism and mechanism of long duration of a highly potent and selective beta₂-adrenoceptor agonist bronchodilator**. *Life Sci* 1993, **52**:2145–2160.
- Richter K, Stenglein S, Mucke M, Sieder C, Schmidtman S, Harnest U, Weidinger G, Magnussen H: **Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD**. *Respiration* 2006, **73**:414–419.
- Bourbeau J, Bartlett SJ: **Patient adherence in COPD**. *Thorax* 2008, **63**:831–838.
- Make BJ: **Chronic obstructive pulmonary disease: developing comprehensive management**. *Respir Care* 2003, **48**:1225–1234.
- Mahler DA, Weinberg DH, Wells CK, Feinstein AR: **The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes**. *Chest* 1984, **85**:751–758.
- Celli B, ZuWallack R, Wang S, Kesten S: **Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes**. *Chest* 2003, **124**:1743–1748.

32. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R: **Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.** *Am J Respir Crit Care Med* 2013, **187**:347–365.
33. Jones P, Beeh K, Chapman K, Decramer M, Mahler DA, Wedzicha J: **Minimal Clinically Important Differences in Pharmacological Trials.** *Am J Respir Crit Care Med* 2014, **189**:250–255.
34. Mahler DA, Decramer M, D'Urzo A, Worth H, White T, Alagappan VK, Chen H, Gallagher N, Kulich K, Banerji D: **Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study.** *Eur Respir J* 2014, **43**:1599–1609.
35. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW: **Bronchodilator reversibility testing in chronic obstructive pulmonary disease.** *Thorax* 2003, **58**:659–664.
36. Price D, Small M, Milligan G, Higgins V, Gil EG, Estruch J: **Impact of night-time symptoms in COPD: a real-world study in five European countries.** *Int J Chron Obstruct Pulmon Dis* 2013, **8**:595–603.
37. Agusti A, Hedner J, Marin JM, Barbe F, Cazzola M, Rennard S: **Night-time symptoms: a forgotten dimension of COPD.** *Eur Respir Rev* 2011, **20**:183–194.
38. Partridge MR, Karlsson N, Small IR: **Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey.** *Curr Med Res Opin* 2009, **25**:2043–2048.
39. Tashkin DP, Pearle J, Iezzoni D, Varghese ST: **Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.** *COPD* 2009, **6**:17–25.
40. Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, Silkoff PE: **Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.** *Drugs* 2009, **69**:549–565.
41. Anzueto A, Ferguson GT, Feldman G, Chinsky K, Seibert A, Emmett A, Knobil K, O'Dell D, Kalberg C, Crater G: **Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes.** *COPD* 2009, **6**:320–329.
42. Campbell M, Eliraz A, Johansson G, Tornling G, Nihlen U, Bengtsson T, Rabe KF: **Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease.** *Respir Med* 2005, **99**:1511–1520.
43. Kerwin E, Rennard S, Gelb A, Rebeda L, Garcia Gil E, Caracta C: **Twice-daily acclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [abstract].** *Am J Respir Crit Care Med* 2011, **183**(1):A1592.

doi:10.1186/s12931-014-0123-0

Cite this article as: D'Urzo *et al.*: Efficacy and safety of fixed-dose combinations of acclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. *Respiratory Research* 2014 **15**:123.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

